The mirabegron dosage used here (50 mg/d) was shown previously to produce white adipocyte “beiging” and improvements in metabolic parameters, including insulin sensitivity in a patient population with obesity that was comparable to that of Beta3-LVH.29,30 Such metabolic effects would be expected to be protective against myocardial remodeling,10 albeit in a time frame possibly longer than the present trial. Here, INS is linked to obesity disorder.